ATE465179T1 - Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden - Google Patents

Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden

Info

Publication number
ATE465179T1
ATE465179T1 AT06291195T AT06291195T ATE465179T1 AT E465179 T1 ATE465179 T1 AT E465179T1 AT 06291195 T AT06291195 T AT 06291195T AT 06291195 T AT06291195 T AT 06291195T AT E465179 T1 ATE465179 T1 AT E465179T1
Authority
AT
Austria
Prior art keywords
scfv
antibodies
bind
post
antibody fragments
Prior art date
Application number
AT06291195T
Other languages
English (en)
Inventor
Luis Barbeito
Mariana Pehar
Patricia Cassina
Pedro M Alzari
Original Assignee
Pasteur Institut
Inst De Investigaciones Biolog
Facultad De Medicina Universid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst De Investigaciones Biolog, Facultad De Medicina Universid filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE465179T1 publication Critical patent/ATE465179T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
AT06291195T 2006-07-24 2006-07-24 Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden ATE465179T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291195A EP1882697B1 (de) 2006-07-24 2006-07-24 Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden

Publications (1)

Publication Number Publication Date
ATE465179T1 true ATE465179T1 (de) 2010-05-15

Family

ID=37075006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06291195T ATE465179T1 (de) 2006-07-24 2006-07-24 Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden

Country Status (10)

Country Link
US (2) US20100055109A1 (de)
EP (2) EP1882697B1 (de)
JP (1) JP5528803B2 (de)
AR (1) AR062038A1 (de)
AT (1) ATE465179T1 (de)
BR (1) BRPI0714545A2 (de)
CA (1) CA2657563A1 (de)
DE (1) DE602006013809D1 (de)
UY (1) UY30501A1 (de)
WO (1) WO2008012049A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE465179T1 (de) * 2006-07-24 2010-05-15 Pasteur Institut Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden
WO2012033916A1 (en) * 2010-09-08 2012-03-15 Southern Illinois University Edwardsville Method for treating chronic pain
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
US20180236031A1 (en) * 2017-02-10 2018-08-23 Vivibaba, Inc Compositions and methods for recombinant nerve growth factor
AU2019243155A1 (en) * 2018-03-27 2020-10-15 Factor Bioscience Inc. Nucleic acid-based therapeutics
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
EP4039269A1 (de) * 2021-02-05 2022-08-10 Dompe' Farmaceutici S.P.A. Ngf-isoform zur verwendung bei der behandlung von augenerkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US6068040A (en) 1998-07-24 2000-05-30 Alpine Overhead Doors, Inc. Slat edge retainer for overhead rolling doors
EP1500399A1 (de) 2003-07-24 2005-01-26 Institut Pasteur Aktive und passive Immunisierung gegen pro-apoptotischen Neurotrophinen zur Behandlung oder Vorbeugung von neurologischen Krankheiten
ATE465179T1 (de) * 2006-07-24 2010-05-15 Pasteur Institut Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden

Also Published As

Publication number Publication date
EP1882697A1 (de) 2008-01-30
HK1116806A1 (en) 2009-01-02
US20140178384A1 (en) 2014-06-26
DE602006013809D1 (de) 2010-06-02
EP1882697B1 (de) 2010-04-21
EP2046823A1 (de) 2009-04-15
US20100055109A1 (en) 2010-03-04
JP5528803B2 (ja) 2014-06-25
UY30501A1 (es) 2009-04-30
WO2008012049A1 (en) 2008-01-31
BRPI0714545A2 (pt) 2013-05-14
CA2657563A1 (en) 2008-01-31
EP2046823B1 (de) 2012-11-21
US9328163B2 (en) 2016-05-03
AR062038A1 (es) 2008-08-10
JP2010501475A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
BRPI0822447A2 (pt) Anticorpo monoclonal e método do mesmo
IL204159A (en) Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
IL197928A (en) A monoclonal antibody munched on steap-1, its immunoconjugates its uses
PT2510011E (pt) Anticorpos monoclonais que se ligam a b7h6 e suas utilizações
IL225752A0 (en) Antibodies that bind transforming growth factor ß and methods for the production thereof
IL219653A0 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
IL202232A0 (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
ZA201003496B (en) Monoclonal antibody capable of binding to anexelekto,and use thereof
HRP20150282T1 (hr) Purifikacija protutijela pomoä†u kromatografije kationskom izmjenom
IL194995A0 (en) Modified humanised anti-interleukin-18 antibodies
IL198592A0 (en) Tes7 and antibodies that bind thereto
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
LT3656793T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
LTC2076540I2 (lt) Nauji anti-cd38 antikūnai, skirti vėžio gydymui
EP2021373A4 (de) Vcam-1-spezifischer monoklonaler antikörper
IL196550A0 (en) Anti-il-6 monoclonal antibodies and uses thereof
BRPI0916915A2 (pt) anticorpos anti-il-17a/f de reatividade cruzada e biespecíficos
BRPI0918178A2 (pt) anticorpos monoclonais para tratamento de câncer
IL220622A0 (en) Monoclonal antibodies against activated and unactivated protein c
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
BRPI1005176A2 (pt) ensaio de insulina, reagente de ensaio de insulina, anticorpo monoclonal, e, método de triar anticorpos monoclonais.
BR112012025082A2 (pt) novos anticorpos monoclonais e método de análise imunológica de dímero-d
DE602006013809D1 (de) Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer
BRPI0814116A2 (pt) Anticorpo monoclonal citotóxico anticâncer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties